Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Kohar K.; Sanjaya I.S.; Amirah S.; Yumnanisha D.A.; Ambari A.M.
Kohar, Kelvin (57536819200); Sanjaya, Indira Saraswati (59092605900); Amirah, Shakira (57782995800); Yumnanisha, Defin Allevia (59092606000); Ambari, Ade Meidian (57189576921)
57536819200; 59092605900; 57782995800; 59092606000; 57189576921
The potential of triglyceride-glucose index in improving the prediction of post-percutaneous coronary intervention clinical outcomes: a systematic review and meta-analysis
2024
Acta Cardiologica
79
5
557
565
8
1
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia
Kohar K., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sanjaya I.S., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Amirah S., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Yumnanisha D.A., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Ambari A.M., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta, Indonesia
Introduction: Despite percutaneous coronary intervention is the current preferred reperfusion modality, the incidence of major adverse cardiovascular events (MACE) is still high. Currently, GRACE score is used for predicting PCI outcomes. The TyG (triglyceride-glucose) index, a potential predictor based on insulin resistance of cardiovascular disease, has not been considered in the GRACE score. Objective: To assess the potential of the TyG index in predicting cardiovascular adverse clinical outcomes in patients undergoing PCI. Method: Following PRISMA guidelines, the authors reviewed literature from five databases. We included studies investigating post-PCI outcomes based on the TyG index level. Effect size was estimated using RevMan to calculate pooled odds ratio and mean difference, and R software to perform diagnostic test accuracy. Results: Overall, 31,671 post-PCI patients with acute coronary syndrome were included in this study. A significant difference in TyG index was found between patients who experienced MACE and those who did not [MD: 0.3 (0.2–0.4), p <.05]. Higher TyG index was strongly correlated with higher MACE [OR: 2.01 (1.45–2.77), p <.05], especially revascularization [OR: 2.40 (1.72–3.36), p <.05], followed by myocardial infarction [OR: 1.80 (2.41–2.86), p <.05], death [OR: 1.36 (0.86–2.15), p =.19], and stroke [OR: 1.09 (0.79–1.50), p =.59]. Tyg Index showed 55% sensitivity, 60% specificity, and 0.612 accuracy. The addition of the TyG index to the GRACE scoring improved the predictive model’s AUC (0.746 vs. 0.809). Conclusion: This systematic review and meta-analysis comprises evidence-based results for the correlation of TyG index and post-PCI outcomes, demonstrating modest sensitivity, specificity, accuracy, and enhanced predictive value of GRACE score. © 2024 Belgian Society of Cardiology.
major adverse cardiovascular effect; percutaneous coronary intervention; prediction model; Triglyceride-glucose index
Acute Coronary Syndrome; Biomarkers; Blood Glucose; Humans; Percutaneous Coronary Intervention; Predictive Value of Tests; Risk Assessment; Risk Factors; Treatment Outcome; Triglycerides; biological marker; triacylglycerol; acute coronary syndrome; area under the curve; Article; cardiovascular disease; cardiovascular mortality; cerebrovascular accident; clinical outcome; diagnostic accuracy; GRACE risk score; heart infarction; human; hyperlipidemia; hypertension; incidence; insulin sensitivity; meta analysis; non insulin dependent diabetes mellitus; obesity; percutaneous coronary intervention; prediction; predictive value; receiver operating characteristic; revascularization; screening; sensitivity and specificity; systematic review; triglyceride-glucose index; blood; diagnosis; glucose bl
Taylor and Francis Ltd.
00015385
38722072
Article
Q3
341
14512